The oral GLP-1 agonist OHP2 reduced Alzheimer's neuroinflammation by inducing astrocyte IL-27 secretion, which reprogrammed microglia from neurotoxic to neuroprotective states via the glycolysis/cGAS lactylation/mTOR pathway.
Oral + BBB crossingOHP2 is an orally available GLP-1 drug that reaches the brain, inducing a specific anti-inflammatory cascade through astrocyte IL-27
What the researchers found
OHP2 induced IL-27 secretion from astrocytes, which modulated microglial reprogramming from neurotoxic M1 to neuroprotective M2 phenotype via glycolysis/cGAS lactylation clock/mTOR pathway, alleviating neuroinflammation.
Why it matters
An oral GLP-1 drug that crosses the blood-brain barrier and reduces Alzheimer's inflammation through a newly identified mechanism could provide accessible, disease-modifying treatment.
How the study worked
In vivo treatment of AD mouse models with oral OHP2, analysis of astrocyte IL-27 secretion, microglial phenotype profiling, and mechanistic pathway dissection.
What this study cannot tell us
Mouse model of AD. The M1/M2 microglial classification is oversimplified. OHP2 is not yet in human trials. The glycolysis/cGAS lactylation pathway needs validation in human tissue.
How to read the evidence
Preclinical study with novel mechanistic pathway identification. Strong mechanistic evidence but early-stage.
When this study was published
Published in 2025.
The bigger picture
This identifies a specific molecular mechanism by which GLP-1 drugs could treat Alzheimer's—not just through general metabolic effects, but through a defined immunomodulatory pathway in the brain.
Questions still open
- Could IL-27 itself be developed as an Alzheimer's therapy?
- Does OHP2 reach therapeutic brain concentrations in humans?
- Is this pathway also engaged by other GLP-1 drugs like semaglutide?
Common questions
How does a diabetes drug help with Alzheimer's?
Can you take this drug by mouth?
Read the original research
IL-27, a metabolic regulator secreted by astrocytes in response to GLP-1RA OHP2, modulates microglial reprogramming in Alzheimer's disease by regulating cGAS lactylation.
Journal of neuroinflammation, 23(1), 58
Citation
Du, Yixuan; Wu, Lingxi; Mao, Yang; Chen, Song; Gao, Xiangdong. (2026). IL-27, a metabolic regulator secreted by astrocytes in response to GLP-1RA OHP2, modulates microglial reprogramming in Alzheimer's disease by regulating cGAS lactylation.. Journal of neuroinflammation, 23(1), 58. https://doi.org/10.1186/s12974-025-03683-1